HUTCHMED (China) (HMDCF) Accumulated Expenses (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Accumulated Expenses came in at $197.6 million in Q2 2026, down 10.6% year-over-year from $221.1 million in Q2 2025, and down 10.6% quarter-over-quarter from $221.1 million in Q2 2025.
Analysis
HUTCHMED (China) (HMDCF) Accumulated Expenses (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Accumulated Expenses for 11 consecutive years, with $197.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Accumulated Expenses fell 10.6% year-over-year to $197.6 million in Q2 2026; TTM through Jun 2026 was $197.6 million, a 10.6% decrease from a year earlier, with the FY2022 full-year figure at $52.6 million, down 75.04% from the prior year.
- Accumulated Expenses was $197.6 million for Q2 2026 at HUTCHMED (China), down from $221.1 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $249.2 million in Q2 2024 and troughed at $52.6 million in Q4 2022.
- A 4-year average of $180.1 million and a median of $209.3 million in 2025 frame the typical range for Accumulated Expenses.
- Across the five-year window, Accumulated Expenses declined 20.53% in 2022 and retreated 10.6% in 2026, its largest moves.
- Over 4 years, Accumulated Expenses stood at $52.6 million in 2022, then soared by 373.54% to $249.2 million in 2024, then dropped by 11.3% to $221.1 million in 2025, then dropped by 10.6% to $197.6 million in 2026.
- The last three Accumulated Expenses figures came in at $197.6 million (Q2 2026), $221.1 million (Q2 2025), and $249.2 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 197.63 Mn |
| Jun 30, 2025 | 221.06 Mn |
| Jun 30, 2024 | 249.22 Mn |
| Dec 31, 2022 | 52.63 Mn |
| Dec 31, 2021 | 66.22 Mn |
| Mar 31, 2021 | 150.33 Mn |
| Dec 31, 2020 | 37.47 Mn |
| Mar 31, 2020 | 1.06 Mn |
| Dec 31, 2019 | 25.95 Mn |
| Sep 30, 2019 | 74.75 Mn |
| Mar 31, 2019 | 64.16 Mn |
| Dec 31, 2018 | 16.29 Mn |
| Dec 31, 2017 | 5.19 Mn |
| Jun 30, 2017 | 27.65 Mn |
| Dec 31, 2016 | 7.55 Mn |
| Jun 30, 2016 | 23.68 Mn |
| Dec 31, 2015 | 4.66 Mn |
| Jun 30, 2015 | 326,000.00 |